Načítá se...
A gene signature associated with PTEN activation defines good prognosis intermediate risk prostate cancer cases
Accurate identification of intermediate risk (Gleason 3 + 4 = 7) prostate cancer patients with low risk of disease progression is an unmet challenge in treatment decision making. Here we describe a gene signature that could guide clinicians in the selection of patients with intermediate stage clinic...
Uloženo v:
| Vydáno v: | J Pathol Clin Res |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5903700/ https://ncbi.nlm.nih.gov/pubmed/29665325 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cjp2.94 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|